Michael A. Morse
Saint Thomas West Hospital(US)Saint Thomas Health(US)Duke University(US)Duke Medical Center(US)Cancer Care Nova Scotia(CA)
Publications by Year
Research Areas
Immunotherapy and Immune Responses, Cancer Immunotherapy and Biomarkers, Colorectal Cancer Treatments and Studies, CAR-T cell therapy research, Immune Cell Function and Interaction
Most-Cited Works
- → Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study(2017)2,758 cited
- → Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose(2008)1,467 cited
- → Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial(2016)1,248 cited
- → A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer(2005)1,103 cited
- → Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial(2016)681 cited
- → NCCN Task Force Report: Management of Patients with Gastrointestinal Stromal Tumor (GIST)—Update of the NCCN Clinical Practice Guidelines